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ABSTRACT
The human AP-endonuclease (APE1/Ref-1), an
essential multifunctional protein, plays a central
role in the repair of oxidative base damage via
the DNA base excision repair (BER) pathway. The
mammalian AP-endonuclease (APE1) overexpres-
sion is often observed in tumor cells, and confers
resistance to various anticancer drugs; its down-
regulation sensitizes tumor cells to those agents
via induction of apoptosis. Here we show that wild
type (WT) but not mutant p53 negatively regulates
APE1 expression. Time-dependent decrease was
observed in APE1 mRNA and protein levels in the
human colorectal cancer line HCT116 p53
(+/+), but
not in the isogenic p53 null mutant after treatment
with camptothecin, a DNA topoisomerase I inhibitor.
Furthermore, ectopic expression of WTp53 in the
p53 null cells significantly reduced both endogen-
ous APE1 and APE1 promoter-dependent luciferase
expression in a dose-dependent fashion. Chromatin
immunoprecipitation assays revealed that endogen-
ous p53 is bound to the APE1 promoter region that
includes a Sp1 site. We show here that WTp53
interferes with Sp1 binding to the APE1 promoter,
which provides a mechanism for the downregulation
of APE1. Taken together, our results demonstrate
that WTp53 is a negative regulator of APE1 expres-
sion, so that repression of APE1 by p53 could
provide an additional pathway for p53-dependent
induction of apoptosis in response to DNA damage.
INTRODUCTION
The mammalian AP-endonuclease (APE1) is a ubiquitous
and remarkably multifunctional protein. It plays a central
role in the base excision repair (BER) pathway for
damaged bases induced by reactive oxygen species and
alkylating agents, and for abasic (AP) sites generated
after excision of oxidized and alkylated bases by DNA
glycosylases (1–3). As an endonuclease, APE1 cleaves the
AP site to generate 30-OH and 50-deoxyribose phosphate
termini, and the 30-OH terminus is utilized by a DNA
polymerase, usually DNA polymerase b, for repair
synthesis in mammalian cells (4). APE1 was independently
identiﬁed as a reductive activator of the c-Jun transcrip-
tion factor in vitro, and named Ref-1 (5). Subsequently,
several other transcription factors (including p53,
hypoxia-inducible factor and NF-kB) were also found to
be activated by APE1 (6–8). In addition, APE1 directly
acts as a trans-acting factor by binding to negative Ca
2+
response elements (nCaRE) during Ca
2+-dependent
repression of the human parathyroid hormone and renin
genes (9–11).
Given its multiple functions, it is not surprising that
APE1 expression is regulated in vivo in a complex manner.
We were one of the ﬁrst to show the activation of APE1
gene by oxidative stress; several other laboratories sub-
sequently conﬁrmed our observation (12–14). Moreover,
based on the identiﬁcation of the nCaREs in the APE1
promoter itself, we suggested that APE1 regulates its own
expression (15). While cell cycle-dependent expression of
APE1 was observed in NIH3T3 cells (16), the basal
expression of APE1 is variable. The increased APE1 level
is often observed in tumor cells including prostate,
osteosarcomas, lung and cervical carcinomas compared
to normal tissues (17–20). In other types of cancer,
subcellular localization of APE1 is altered relative to
that in normal tissues (21–23). Tumor cells often over-
express APE1 and are resistant to chemotherapeutic
drugs and ionizing radiation (19,24,25). In contrast,
siRNA-mediated downregulation of APE1 induced apop-
tosis of many tumor cell types and enhanced cell
sensitization to ionizing radiation and chemotherapeutic
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tion-induced apoptosis in mouse embryo ﬁbroblasts
(MEF) conditionally nullizygous for endogenous APE1,
an eﬀect that could be prevented by ectopic expression of
human APE1 (29). Using a complementation assay, we
also showed that both the repair and transcription
regulatory functions of APE1 are required to prevent
apoptosis of MEF (29). Thus, elucidating the molecular
mechanisms controlling APE1 expression has profound
implications for cancer therapy from both basic and
clinical perspectives.
The tumor suppressor gene p53, dubbed ‘the guardian
of the genome’, encodes a sequence-speciﬁc transcription
factor that activates a variety of cellular genes in response
to DNA damage, hypoxia and other stress signals (30,31).
p53 is one of the most commonly mutated genes in human
cancers; 50% of all human cancers lack the wild type
(WT) p53 gene allele, and these tumors respond poorly
to chemotherapy (32,33). In response to DNA damage or
other cellular stresses, p53 is activated and induces cell
cycle arrest or apoptosis, depending on the severity of the
damage and the context of the cell cycle, and thus helps
to maintain genomic stability and prevents cancer (34).
Once activated, p53 has the ability to arrest cell cycle by
transactivation of Waf-1/p21, 14-3-3d etc., or induce cells
to undergo apoptosis by both transcription-dependent and
-independent mechanisms (35–37). p53 activates many
downstream target genes involved in the mitochondrial
signaling pathway during apoptosis including BAX,
PUMA and the death receptor (38–40). In addition, p53
has been shown to downregulate many genes, including
cell survival genes such as survivin, bcl-2, IGF1R and DNA
repair gene O
6-methylguanine-DNA-methyltranferase
(MGMT) with the net result of facilitating apoptosis
induction (41–46).
Potential link between APE1 expression and p53 status
in various tumors and their resistance to chemotherapeu-
tic drugs have been documented (24,47). Despite several
studies showing the involvement of APE1 and p53 in drug
resistance induction in tumor cells, the question of
whether p53 regulates APE1 expression after genotoxic
stress has not been addressed. Elucidating the direct role
of p53 on APE1 gene expression in human cells should be
of major clinical signiﬁcance, and a clear understanding of
the mechanisms by which p53 controls APE1 expression
could help in eﬀective use of chemotherapeutic agents in
the treatment of tumors expressing WT or mutant p53.
In this study, we show that activation of p53 after geno-
toxic stress downregulates APE1 expression in HCT116
p53
(+/+) human colon carcinoma cells, but not in the p53
null mutants derived there from. Transgenic expression of
WTp53 in p53 null cells downregulate both endogenous
APE1 level and expression of a reporter whose activity is
dependent on APE1 promoter activity. We also present
evidence that p53 is associated with the endogenous APE1
promoter in vivo, and that interference of speciﬁcity
protein (Sp1) binding to the APE1 promoter by WTp53
and subsequent recruitment of histone deacetylase
(HDAC) to the promoter could explain downregulation
of APE1 by WTp53.
MATERIALS AND METHODS
Cell cultureand treatment
The human colorectal adenocarcinoma lines, HCT116
p53
(+/+) with WTp53 and p53 null HCT116 p53
( / )
(a gift from Dr B. Vogelstein, Johns Hopkins University
School of Medicine) were grown in McCoy’s 5A (Gibco
Life Technologies, Carlsbad, CA, USA) medium supple-
mented with 10% fetal bovine serum (Sigma-Aldrich,
St Louis, MO, USA), 100U/ml penicillin and 100mg/ml
streptomycin (Gibco BRL, Carlsbad, CA, USA) in a 5%
C02 incubator at 378C. Cells were treated with 200nM
camptothecin (CPT) (Sigma, St Louis, MO, USA) and/or
30mM piﬁthrin-a (PFT-a) (Sigma, St Louis, MO, USA).
Plasmids and luciferase assays
Generation of APE1 promoter–reporter plasmids contain-
ing DNA fragments ( 4800/+65) and ( 1800/+65) of
the 50 regulatory region was described earlier (15). Other
reporter plasmids with various lengths of the APE1 50
regulatory region were generated by PCR and cloned into
the luciferase reporter vector pGL3 (Promega, Madison
WI, USA) using standard procedures. HCT116 p53
( / )
cells were cotransfected with 500ng of the APE1-reporter
plasmids and expression plasmids for WT or mutant
[Val143Ala (V143A) and L22G, T23S] p53 or equivalent
amounts of empty vector using LipofectAMINE 2000
(Invitrogen, Life Technologies, Carlsbad, CA, USA),
according to the manufacturer’s instructions. At 48h
after the transfections, cells were lysed with the reporter
lysis buﬀer (Promega), and the luciferase activity in the
cell lysates was measured in a luminometer (AutoLumant
LB593, Berthold, Oak Ridge, TN, USA) by the luciferase
assay kit (Promega, Madison, WI, USA) according to the
manufacturer’s protocol. The luciferase activity was
normalized to the amount of protein in the lysate.
Preparation of total cell extractand western blot analysis
HCT116 cells were lysed in a lysis buﬀer (50mM Tris-
HCl, pH 7.5, 150mM NaCl, 1mM EDTA, 1% TritonX-
100, and protease inhibitor cocktail (Roche, Nutley NJ,
USA) as described earlier (48). Whole-cell extracts (25mg)
were subjected to 12.5% SDS–PAGE and transferred to a
nitrocellulose membrane (Trans-Blot 0.2mm, Bio-Rad,
Hercules, CA, USA). Western immunoblotting analyses
with mouse monoclonal antip53 antibody (sc-DO-1,
dilution 1:200, Santa Cruz Biotechnology, CA, USA),
rabbit polyclonal antiAPE1 (dilution 1:2000), or rabbit
monoclonal antib-actin antibody (Sigma, 1:1000 dilution)
were carried out using enhanced chemiluminescence assay
(ECL kit, Amersham, London, UK).
RNA isolation and RT-PCR analysis
Total RNA was extracted using Rneasy Mini kit
(QIAGEN) according to the manufacturer’s protocol.
For quantitative, real-time RT-PCR, one step RT-PCR
was performed with 100ng of cellular RNA for both the
target gene and an endogenous control in singleplex tubes
using TaqMan one-step RT-PCR master mixture reagent
kit (P/N 4309196). TaqMan MGB probes (FAMTM
1556 Nucleic Acids Research, 2008, Vol. 36, No. 5dye-labeled) for APEX1 gene and 18s rRNA (VICTM-dye
labeled probe) TaqMan assay reagent (P/N 4319413E)
for endogenous control (assay-on-DemandTM (P/N
4331182) were used. The cycling parameters in an ABI
7000 (Applied Biosystem, Foster City, CA, USA) thermal
cycler were as follows: reverse transcription at 488C for
30min. AmpliTaq activation 958C for 10min, denatura-
tion 958C for 15s, and annealing/extension 608C for 1min.
The amount of target was calculated after normalization
to the 18s RNA as an endogenous control.
Chromatin immunoprecipitation (ChIP) assay
HCT116 p53
(+/+) and HCT116 p53
( / ) cells were treated
with CPT at ﬁnal concentration of 200nM for 6h unless
otherwise indicated. Cells were washed twice with ice-cold
PBS, ﬁxed with 1% formaldehyde for 10min at RT,
washed twice with cold PBS, and harvested in cell scraping
solution (1X PBS and 0.5mM PMSF). Pellets were
collected by centrifugation at 1200rpm for 10min at 48C
and resuspended in ice-cold lysis buﬀer (Active Motif,
ChIP-IT, Carlsbad, CA, USA, supplemented with 0.5mM
PMSF and 0.5mM protease inhibitor cocktail), and then
incubated on ice for 30min. The DNA fragments were
digested with mung bean nuclease to an average size of
200–500bp, as empirically estimated by agarose gel
electrophoresis of the digest. Immunoprecipitations were
performed with antip53 (DO-1), IgG (as a negative
control) and antiSp1 (as a positive control) antibodies.
After sequential washing, DNA–protein complexes were
eluted with elution buﬀer (1% SDS, 0.1M NaHCO3,
0.01mg/ml herring sperm DNA). The crosslinks were
reversed by heating at 658C overnight, and treatment with
proteinase K (0.17mg/ml) for 1h, and the DNA then
isolated using a column (Active Motif, ChIP-IT) accord-
ing to the manufacturer’s guidelines. Recovered DNA was
suspended in 50ml of TE. PCR ampliﬁcation of DNA was
carried out with diluted aliquots using appropriate
primers to generate PCR products spanning +24 to
 368bp and  118 to  253bp of the APE1 promoter
region. The PCR products were separated by 1.5%
agarose electrophoresis in Tris-borate-EDTA buﬀer and
stained with ethidium bromide.
Electrophoretic mobility shiftassay(EMSA)
Electrophoretic mobility shift analyses were performed
as described earlier (38) with some modiﬁcations. The
50 32P-labeled oligo 50-AGAGAGGGAGGCGAGGCTA
AGCGTCTCCGTCACGT-30 (potential p53-binding site
on APE1 promoter) and 50-TTG AAC ATG TCC CAA
CAT GTT GA-30 containing the p53 consensus sequence
from the human p21 promoter were annealed with
appropriate complementary stands to generate duplex
oligos. The DNA (50fmol) was then incubated with p53
or nuclear extracts (5mg) from HCT116 p53
( / ) cells for
20min at 258C in a buﬀer containing 40mM HEPES-
KOH, pH 7.5, 50mM KCl, 1mM MgCl2, 0.5mM EDTA,
0.5mM DTT, 10% glycerol, 1mg of poly dI-dC (Sigma).
After electrophoresis in non-denaturing 5% polyacryla-
mide gels in Tris-borate buﬀer at 48C, the gels were
dried and exposed to PhosphorImager (Molecular
Dynamics, Piscataway, NJ, USA) and analyzed using
IMAGEQUANT software.
RESULTS
WTp53downregulates APE1 mRNA andprotein levels
We examined the eﬀect of WTp53 on APE1 expression
in HCT116 p53
(+/+) and HCT116 p53
( / ) cell lines. To
activate p53, these cells were treated with CPT, a DNA
topoisomerase I inhibitor, and total RNA was isolated
at the indicated times for quantitation of APE1 mRNA
levels by real-time RT-PCR. We observed a signiﬁcant
decrease in the APE1 mRNA level at 18h after treatment
with CPT with simultaneous activation of WTp53 in
HCT116 p53
(+/+) cells (Figure 1A). Treatment with CPT
also reduced APE1 mRNA level in p53-negative HCT116
p53
( / ) cells, although not to the same extent as in the
p53
(+/+) cells indicating a relationship between the p53
status and the downregulation of APE1 expression.
Treatment with CPT also induced the p21 level in
HCT116 p53
(+/+) cells concomitant with enhanced p53
levels (Figure 1B). Activation of the p21 gene was used to
monitor in vivo function of p53. Although a transient
increase in the APE1 protein level was observed soon after
(1h) CPT treatment, consistent with the decreased APE1
mRNA level, the APE1 polypeptide level was also
signiﬁcantly reduced in HCT116 p53
(+/+) cells at 18h
after treatment with CPT (Figure 1B, right panel).
We further conﬁrmed the role of p53 by treating
cells with the water soluble p53 inhibitor PFT-a, which
blocked activation of p53-regulated genes, including
cyclin G, p21/Waf-1 and mdm2, and also inhibits
apoptosis (49–51). Treatment with PFT-a attenuated
APE1 repression after CPT treatment in p53
(+/+) cells
(Figure 1C), while it had no eﬀect on the APE1 level in
p53
( / ) cells (Figure 1D). Taken together, these results
suggest that downregulation of APE1 expression is
p53-dependent.
To further conﬁrm that WTp53 acts as a negative
regulator of APE1 expression, we investigated the eﬀect of
WTp53 overexpression on the APE1 protein and mRNA
levels in HCT116 p53 null cells. Various amounts of
expression plasmid for WTp53 were used for transfection
of p53 null cells, and the expression of p53 and p21 was
conﬁrmed by western analysis of the cell extracts
(Figure 2A). Overexpression of p53 decreased APE1
mRNA and protein levels in a dose-dependent manner
(Figure 2A and B). To conﬁrm that ectopic p53 was
transcriptionally active, we measured the p21 levels in
nuclear extracts of p53-transfected cells (Figure 2C), and
its binding to double-stranded oligonucleotides containing
the p53-binding motif of the p21 promoter. Figure 2C
shows predominant localization of p53 in nuclear fraction
of cells after ectopic expression of WTp53. EMSA of the
same extract conﬁrmed the presence of WTp53 which
formed a shifted complex with the p53 cis sequence
(Figure 2D). Together, these results further conﬁrm that
p53 acts as a repressor of APE1 expression.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1557APE1promoter activity is repressed by WTp53,but not
bymutant p53
To determine whether p53-mediated downregulation
of APE1 occurred at the promoter level, we exam-
ined the eﬀect of p53 overexpression on APE1 promo-
ter-dependent luciferase activity in a transient reporter
expression assay. We cotransfected an APE1 promoter
luciferase reporter construct ( 4000/+65 APE1-Luc,
containing the APE1 promoter sequence from  4000 to
+65bp) and the WTp53 expression plasmid into HCT116
p53
( / ) cells. Ectopic expression of WTp53 induced a
dose-dependent decrease in APE1 promoter activity (up to
250-fold compared to the vector control, Figure 3A).
Increase in p53 expression was conﬁrmed by western
analysis of the same cells extract with antip53 antibody
(Figure 3B). Because p53 is an activator of the p21 gene,
we simultaneously examined the eﬀect of ectopic expres-
sion of p53 on p21 promoter-dependent luciferase activity.
The increase in p21 promoter-dependent luciferase activity
with increasing amounts of input p53 plasmid indicated
that the inhibitory eﬀect of p53 on APE1 promoter was
not due to general inhibition of transcription (Figure 3C).
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Figure 1. Repression of APE1 gene expression in HCT116 p53
(+/+) cells after CPT treatment. (A) Real-time RT-PCR analysis of APE1 mRNA
from HCT116 p53
(+/+) and HCT116 p53
( / ) cells at indicated time points after CPT treatment. Results correspond to mean SD from three
separate experiments. (B) After treating HCT116 p53
(+/+) cells with CPT (200nM), as described under Materials and Methods section, total lysates
of cells harvested at the indicated times were analyzed for p53, APE1 and p21 levels by western blotting. b-actin was used as the loading control.
Right panel, graphical representation of APE1 protein level (normalized to b-actin) at indicated time points after CPT treatment. Results correspond
to mean SD from three separate experiments. (C and D) HCT116 p53
(+/+)or p53
( / ) cells were treated with CPT (200nM) for 24h in the presence
or absence of the p53 inhibitor PFT-a and total lysates were analyzed for p53, APE1 and p21 levels by western blotting. b-actin was used as the
loading control. Right panel, graphical representation of APE1 protein level (normalized to b-actin) after treatment with CPT or PFT-a. Results
correspond to mean SD from three separate experiments;
 P<0.05.
1558 Nucleic Acids Research, 2008, Vol. 36, No. 5Moreover, we observed that CMV promoter-dependent
b-galactosidase and thymidine kinase promoter-dependent
renilla-luciferase (pRL-TK, Promega) levels were also
increased due to overexpression of WTp53 for unknown
reasons (data not shown). We thus could not therefore use
these reporter plasmids for normalizing transfection
eﬃciency. In any case, our results indicate that the p53-
dependent repression is APE1 promoter speciﬁc, and
not a general phenomenon. We also examined the eﬀects
of two p53 point mutants on APE1 promoter activity
namely, V143A, a missense mutation which inactivates
p53’s sequence-speciﬁc DNA binding, and a Leu22Gln
Trp23Ser (22,23), double mutant which retains the ability
to bind p53-cis sequences but lacks transcriptional
activation ability (52). Overexpression of WTp53 signiﬁ-
cantly decreased luciferase activity under the control of
the APE1 promoter (reaching up to  60-fold with 50ng of
WTp53), while the mutants had no signiﬁcant inhibitory
eﬀect (Figure 3D). Western analysis of p53
( / ) cells
lysates transiently transfected with p53 expression plas-
mids revealed that the p53 mutant polypeptides were more
stable than the WT protein, and were present at higher
levels (2- to 3-fold, Figure 3E). These results indicate that
despite these higher levels, mutant p53 could not inhibit
the APE1 promoter activity.
Identification of p53-responsive ciselement(s)
inAPE1 promoter
To identify the cis element(s) responsible for p53-mediated
downregulation of the APE1 promoter, we carried out
promoter deletion analysis. We have shown earlier that
the APE1 promoter contains multiple negative regulatory
and enhancer elements, including two nCaRE-B elements
upstream ( 4000 to  1800bp) of the basal promoter (15).
To test whether p53-induced repression of APE1 promoter
activity is mediated through the cis elements located
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Figure 2. Decreased APE1 protein and mRNA levels after ectopic expression of WTp53 in p53 null cells. (A) Total cell extracts were analyzed for
p53, APE1 and p21 levels by western blotting. b-actin was used as the loading control. Right panel, graphical representation of APE1 protein level
(normalized to b-actin) after transfection with various amounts of WTp53 expression plasmid. Results correspond to mean SD from three separate
experiments. (B) Real-time RT-PCR analysis of APE1 mRNA levels in HCT116 p53
( / )cells transfected with various amounts of WTp53 expression
plasmid and incubated with PFT-a or vehicle for 48h. Results correspond to mean SD from three separate experiments. (C) Western analysis of
p53 and p21 levels in nuclear fraction in p53 null cells after ectopic expression of WTp53. Lamin B was used for nuclear extracts loading control. (D)
EMSA of nuclear extracts used in (C) using
32P-labeled duplex oligo from p21 promoter containing consensus p53-binding sequence;
 P<0.05.
Nucleic Acids Research, 2008, Vol. 36, No. 5 1559in this region, we cotransfected HCT116 p53
( / ) cells
with WTp53 and the reporter plasmid containing  1800
to +65bp ( 1800/+65 APE1-Luc) of the APE1 promo-
ter. Deletion of the promoter sequence from  4000 to
 1800bp signiﬁcantly increased the basal promoter
activity ( 9-fold, Figure 4A), conﬁrming our earlier
observation about the presence of negative regulatory
elements within this sequence (15). Furthermore, ectopic
expression of WTp53 caused a decrease in the promoter
( 1800/+65 APE1-Luc) activity in a dose-dependent
manner (Figure 4B).
We then carried out detailed mapping of the p53
regulatory sequence by using a series of 50 promoter
deletion constructs. DNA fragments of the 50 regulatory
region (shown in Figure 5A) were cloned upstream of the
luciferase coding region and their promoter activity was
determined by cotransfection as before. All deletion
constructs except 7 and 8 showed basal promoter activity
that was abolished by deleting residues  143 to  118
(Figure 5A and B) indicating that the sequence upstream
of  118 is required for basal promoter activity. Although
deletion of  4000 to  1800 decreased p53-mediated
downregulation of promoter activity by  1.5-fold, lucifer-
ase activity of all the deletion constructs was signiﬁcantly
downregulated after cotransfection with WTp53
(Figure 5B). However, elimination of the sequence from
 184 to  143 (construct number 6, Figure 5A) abolished
the inhibitory eﬀect of p53 (Figure 5B), indicating that the
cis element involved in p53-dependent repression is
localized within this sequence. Furthermore, deletion of
the +65bp region downstream to the transcription start
site (construct number 5, Figure 5A) had no eﬀect on p53-
mediated repression, indicating that these sequences are
not required for repression (Figure 5B). Thus the p53-
responsive cis elements appeared to be located within
the proximal region ( 184 to  143bp) of the APE1
promoter.
Lack of directbinding of p53to the APE1promoter in vitro
To identify the putative p53-responsive cis element(s) in
the 41bp ( 184 to  143) APE1 promoter sequence, we
performed a computer search for potential transcription
factor binding sites. Putative binding sites were identiﬁed
one each for Sp1 and upstream factor (USF); however, no
consensus p53-binding site could be shown even allowing
for two mismatches. Nevertheless, we tested for a
potential binding site for p53 in this 41bp sequence by
EMSA using a recombinant p53 polypeptide. The p53 cis
element present in the p21 promoter was used as a positive
control. As shown in Figure 6A, puriﬁed p53 can bind to
the p21 promoter (lane 2), but not to the APE1 promoter
sequence (lanes 4 and 5), indicating a lack of direct p53
binding to the APE1 promoter in vitro.
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Figure 3. Inhibition of APE1 promoter activity by WT but not mutant
p53. (A) p53
( / ) cells were transiently transfected with (0.5mg) of
APE1 promoter–luciferase plasmid ( 4500/+65) and various amounts
of WTp53 expression plasmid or control vector. Luciferase activity was
measured at 48h after transfection and normalized for the amount of
protein. The mean SD of ﬁve independent experiments performed in
duplicate is shown. (B) Western analysis of the p53 level in the
transfected cell extracts used in (A). (C) p53
( / ) cells were cotrans-
fected with (0.5mg) of p21 promoter–luciferase plasmid and WTp53.
Luciferase activity was measured 48h after transfection and normalized
for the amount of protein. (D) p53
( / ) cells were transiently
transfected with (0.5mg) of APE1 promoter–luciferase plasmid
( 4500/+65) and 0.05mg of expression plasmid encoding WTp53 or
mutant p53 (V143A) (22,23) or equivalent amount of empty vector.
Other details are given above. (E) Western analysis of WT and mutant
p53 in cells lysates used in (D);
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  P<0.001.
1560 Nucleic Acids Research, 2008, Vol. 36, No. 5Recruitment ofp53 to theAPE1 promoter isinduced
by cellular stress
Because p53 could exert its repressor activity via interac-
tion with other transcription factors bound to their
cognate promoters, we used ChIP assay to test whether
p53 is associated with the APE1 promoter in vivo (41).
p53
(+/+) and p53
( / ) HCT116 cells were treated with
CPT for 6h, and subsequently with 1mM disuccinimidyl
glutarate, which produces protein–protein crosslinks,
followed by further incubation with 1% formaldehyde to
produce protein–DNA crosslinks. The chromatin frac-
tions were isolated and fragmented by digestion. After
immunoprecipitation with antibody to p53 or Sp1, ChIP
assays were then performed as described in Materials and
Methods section. The amount of immunoprecipitated
APE1 promoter sequence was quantitated for each sample
by PCR analysis with primers for ampliﬁcation of the
APE1 promoter region from  368 to +24bp. Figure 6B
shows signiﬁcant enrichment of this sequence in the
immunocomplex with p53 antibody, indicating that p53
is associated with the APE1 promoter in vivo in HCT116
p53
(+/+) cells. We performed appropriate control experi-
ments to validate our results. Thus, no signiﬁcant
enrichment of the APE1 promoter sequence was observed
by the PCR assay in the p53 immunoprecipitate from
chromatin fraction of p53
( / ) cells (Figure 6B). Similarly,
no signiﬁcant enrichment of the APE1 promoter sequence
was observed in chromatin extracts from either cell line
when non-speciﬁc IgG was used for immunoprecipitation
(Figure 6B). An earlier study identiﬁed overlapping Sp1-
binding sites within this APE1 promoter sequence (53). As
expected, signiﬁcant enrichment of the APE1 promoter
sequence was observed in the Sp1-speciﬁc immunocom-
plexes from both cell lines (Figure 6B), indicating that Sp1
is constitutively associated with the APE1 promoter in the
chromatin fraction of both p53
(+/+) and p53
( / ) cells. To
establish that p53 selectively binds to this ( 184 to
 143bp) sequence, we used appropriate primer sequences
to amplify the region corresponding to  253 to  118bp
of the APE1 promoter. Figure 6C shows that this
sequence was selectively enriched in the p53 immuno-
complex from the p53
(+/+) but not p53
( / ) HCT116 cells.
This conﬁrms binding of p53 to this sequence in vivo.
These results provide strong evidence that both p53 and
Sp1 are associated with the  253 to  118bp region in the
human APE1 promoter in vivo.
Although there is no evidence for a p53-speciﬁc cis
element in the APE1 promoter, the presence of p53 in the
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Figure 5. (A) Schematic diagram of the APE1 promoter 50 regulatory
region showing the location of DNA fragments cloned upstream of the
luciferase-coding region. The nucleotides are numbered 50( ) and 30(+)
from the transcription start site (+1). (B) p53
( / ) cells were
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Figure 4. Eﬀect of WTp53 on APE1 promoter reporter activity.
(A) Basal promoter activity of APE1 promoter luciferase constructs
containing  4500 or  1800bp of APE1 promoter sequences linked to
the luciferase gene. (B) p53
( / ) cells were transiently transfected with
0.5mg of APE1 promoter–luciferase plasmid ( 1800/+65) and WTp53
or control vector as before. Luciferase activity was measured 48h after
transfection as before;
 P<0.05.
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strongly supports the idea that p53 is recruited to the
APE1 promoter via binding to some other trans-acting
factors. p53 has been shown to interact with several
factors of the basal transcription machinery, e.g. TATA-
binding Protein (TBP) or the basal transcription factor
Sp1, and also to recruit mSin3A/HDAC repressor
complex to the promoter to inhibit transcription (41).
Consistent with this, p53-mediated repression of several
promoters has been shown to be reversed with the HDAC
inhibitor, tricostatin A (TSA) (54,55). To test possible
involvement of HDAC in p53-mediated APE1 repression,
we used the  1800/+65 APE1-Luc promoter–reporter
plasmid which showed the highest promoter activity. At
24h after cotransfection of HCT116
( / ) cells with the
APE1 promoter–reporter and WTp53 plasmids, the cells
were treated with 100ng/ml TSA. Figure 7A shows that
TSA reversed p53-mediated repression of luciferase to a
signiﬁcant extent, suggesting that the repression involves
p53-dependent recruitment of HDAC to the APE1
promoter.
P53-induced APE1repression is mediated by interference
with Sp1bindingto theAPE1 promoter
Identiﬁcation of one Sp1 site within the putative p53
response element in the APE1 promoter raised the
possibility that p53 is recruited by Sp1 to the APE1
promoter complex for inhibition (Figure 7B). ChIP
analysis clearly demonstrated association of Sp1 and p53
in the APE1 promoter complex (Figure 6B). p53 has been
shown to bind Sp1 and interferes with its binding to the cis
element for Sp1-mediated transcription (56–58). To test
this possibility, we performed EMSA with APE1’s Sp1-
binding sequence. Formation of speciﬁc protein–DNA
complexes suggested the binding of Sp1 to the oligo
(Figure 7C), which was competed with unlabeled oligo
containing WT but not a mutated Sp1 oligo sequence.
These data conﬁrm the speciﬁcity of Sp1 binding to this
sequence. Furthermore, a signiﬁcant decrease in binding
was observed with nuclear extract from p53-overexpres-
sing HCT116
( / ) cells, suggesting that WTp53 interferes
with Sp1 binding to the promoter.
p21 oligo. + + −−−
− + − ++
− − + ++
Recombinant WTp53
APE1  oligo.
−253 −118
+65
HCT116  p53(+/+)
HCT116 p53(−/−)
Input p53
+65
−368 +24
HCT116  p53(+/+)
HCT116 p53(−/−)
Input      Ig Gp 53     Sp1
Antibodies
Antibodies
A
B
C
123 4 5
IgG Sp1
Figure 6. ChIP assay for in vivo association of p53 with APE1 promoter. (A) EMSA of puriﬁed p53 (60ng, lane 4; 120ng, lane 5) using
32P-labeled
duplex oligo corresponding to the bases ( 184 to 142) from the APE1 promoter sequence or containing consensus p53-binding sequence from the
p21 promoter (lane 2) as a control. (B) p53
(+/+) cells were treated with CPT for 9h, the protein–DNA was crosslinked, and ChIP assays performed
as described in Materials and Methods section. Immunoprecipitated APE1 promoter with the indicated antibody was ampliﬁed with primers as
described in Materials and Methods section. Left panel, schematic diagram of the APE1 promoter showing the relative position of PCR primers used
in the ChIP assays.
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APE1 is often overexpressed in tumor cells compared to
its basal level in many untransformed cells lines.
Downregulation of APE1 was found to sensitize tumor
cells to chemotherapy with induction of apoptosis
(26,27,29). Thus, elucidating the molecular basis for
variable APE1 expression is important from both basic
and clinical perspectives. Although several studies have
shown that p53 participates in DNA repair processes, and
stimulates BER via its direct interaction with APE1 and
DNA polymerase b, whether p53 regulates APE1 level
itself was not shown before (59). This report provides the
ﬁrst evidence that p53 downregulates APE1 expression.
We have shown that the levels of both APE1 mRNA and
polypeptide were decreased after CPT treatment in
HCT116 p53
(+/+), but not in the isogenic HCT116
p53
( / ) cells. This eﬀect on HCT116 p53
(+/+) cells was
speciﬁc, and not a consequence of general eﬀects of
genotoxic or other types of stress, because the same
treatment did not aﬀect APE1 expression in p53 null cells.
This thus indicates direct relationship between the p53
status and APE1 downregulation. Reduced expression of
both endogenous APE1 and APE1 promoter-dependent
luciferase activity by exogenous p53 in unstressed p53 null
cells further conﬁrmed that p53 downregulates APE1
expression. However, ectopic expression of WTp53 down-
regulated the episomal APE1 promoter to a much greater
extent than the endogenous gene which was somewhat
unexpected. It is possible that the APE1 promoter in the
chromatinized plasmid is more sensitive to the eﬀect of
p53 than the folded conformation in cellular chromatin.
Furthermore, the endogenous APE1 gene could be
regulated by binding of transcription factors to cis
elements absent in the episomal promoter. The V143A
p53 mutant lacking DNA-binding activity did not down-
regulate the basal APE1 promoter as much as did WTp53,
which strongly suggests that p53’s DNA-binding ability
is a prerequisite for its repressor activity. However, the
L22G, T23S double mutant with normal DNA-binding
activity, but lacking trans-acting activity (52), was also
unable to repress the APE1 promoter, which suggests that
both DNA binding and transactivation abilities of p53 are
required for the repression. Western analysis showing that
p53 mutants were more stable than the WTp53 protein
eliminated the possibility that the former’s inability to
repress the APE1 promoter was due to reduced stability.
Using functional analysis of nested deletion mutants,
we mapped the basal APE1 promoter to a  143bp
segment 50 to the transcription start site. We also observed
that the candidate p53-responsive cis element(s) were
located in the  184 to  143bp segment. However,
sequence analysis revealed no apparent p53-binding sites
within this segment. Moreover, the recombinant p53
polypeptide failed to bind to an oligo of this sequence
( 184 to  143). At the same time we have provided direct
evidence from ChIP assays that p53 was bound to the
 253 to  118bp segment sequence in vivo. Together, these
data suggest that APE1 repression by p53 is not mediated
via direct cis element binding, but rather involves p53’s
indirect recruitment to the promoter by other transcrip-
tion factors. p53 has been shown to repress many other
promoters that lack p53-speciﬁc cis elements, indicating
that the mechanisms of p53-mediated repression are
varied and complex (41,58,60,61). Such mechanisms
could include (i) interference with transcriptional activa-
tors, (ii) interference with the basal transcription machin-
ery and (iii) compaction of the chromatin structure at the
promoter sites by recruitment of HDACs and other
histone-modifying enzymes (41).
The exact mechanism by which p53 represses the APE1
expression is not clear. We have shown that candidate
p53-responsive element(s) were located in the  184 to
 143bp segment that includes one Sp1 site. An earlier
study using in vitro DNase I footprinting analysis with
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Figure 7. Eﬀect of TSA on p53-mediated repression of APE1 promoter
activity. (A) p53
( / ) cells were transiently transfected with 0.5mg
of APE1 promoter–luciferase plasmid ( 1800/+65) and increasing
amounts of expression plasmid encoding WTp53 or equivalent amounts
of empty vector. Twenty-four hours after transfection cells were treated
with or without TSA (100ng/ml) and luciferase activity was measured
48h after transfection and normalized for the amount of protein. The
mean SD of ﬁve independent experiments performed in duplicate is
shown. (B) Sequence of the DNA probes for EMSA assay with APE1
promoter. Schematic diagram of the APE1 promoter showing some of
the putative transcription factor binding sites (Sp1; USF; glucocorticoid
response element (GRE); activator protein 1 (AP-1); and CCAAT box-
like sequence). (C) EMSA with nuclear extracts of p53
( / ) cells
transfected with empty vector or WTp53 expression plasmid using
32P-labeled duplex oligo corresponding to bases  177 to  143 from
APE1 promoter;
 P<0.05.
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spanning  169 to  148bp in the APE1 promoter (53).
Consistent with this, our ChIP assay showed constitutive
Sp1 binding within this region in both p53
(+/+) and
p53
( / ) cells, indicating that the Sp1 site is functional
in vivo. Moreover, we observed that Sp1 remains bound to
the APE1 promoter after p53 activation by CPT,
suggesting that both p53 and Sp1 can simultaneously
occupy the same promoter region. It thus appears that
repression may be achieved through the physical interac-
tion of p53 with Sp1. Consistent with this possibility, p53
has been shown to bind Sp1, inhibiting Sp1-mediated
transcription (56–58). However, in P53-dependent repres-
sion of the telomerase reverse transcriptase, insulin
receptor, VEGF and POLD1 genes, p53 does not inhibit
DNA binding by Sp1, but rather interferes with its ability
for transactivation (57,58,60–63). We also observed that
overexpression of p53 decreased DNA binding by Sp1. On
the other hand, treatment with HDAC inhibitor TSA
partially abolished p53-mediated repression of the APE1
promoter indicating HDAC recruitment to the promoter
site. Thus the mechanism of p53-mediated repression of
the APE1 gene appears to be multifaceted.
Our ﬁndings are intriguing because p53 acts as a pro-
apoptotic factor in the cellular response to stress, whereas
APE1 is a pro-survival protein whose DNA repair
function is essential for protecting cells from oxidative
damage (28,29). However, it is possible that the tumor
suppressor function of p53 is mediated in part by
transcriptional repression of antiapoptotic genes such as
APE1. Thus the cell could use p53 to downregulate APE1
expression in response to severe DNA damage, thereby
promoting apoptosis. Consistent with this idea, several
earlier studies showed reduction of APE1 expression
during apoptosis in myeloid leukemia cells and in neurons
after transient global cerebral ischemia in rats (64,65).
Additional studies are needed to unravel the physiological
signiﬁcance of such downregulation.
Our study also sheds light on the potential link between
APE1 expression and p53 status in diﬀerent tumors with
their resistance to chemotherapeutic drugs. Although
only few published studies have directly focused on the
potential link between APE1 expression and p53 status in
various tumors, an inverse relationship between APE1
nuclear expression and p53 nuclear accumulation has been
reported in head and neck cancer (24,47). It is interesting
to speculate that tumors with mutated p53 also have high
APE1 levels and develop resistance to therapy, while
induction of WTp53 in other tumors will reduce their
APE1 levels, leading to enhanced therapeutic index of
eﬃcacy of the anticancer drugs. Thus the p53-mediated
suppression of APE1 expression could oﬀer a potential
approach for sensitizing tumor cells to drugs.
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